Pfizer

Generic versions of major depression drug availableMylan received approval from FDA to market its desvenlafaxine extended-release tablets, the generic version of Pristiq (Pfizer), for major depressive disorder. Plus, 2 other manufacturers recently received approval for their generic versions of Pristiq.
Pfizer Receives FDA Warning
Pfizer Receives FDA WarningA Pfizer plant in Kansas is putting patients at risk, according to the FDA
Fasting regimens may be key in treating type 2 diabetesFasting regimens have gained popularity as a technique for reducing weight and obesity. This strategy may improve insulin sensitivity in patients with insulin resistance and diabetes.
Breast cancer biosimilar shows equivalency to brand
Breast cancer biosimilar shows equivalency to brandTwo new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.
New Products: Test launched to improve prostate biopsy decision processOther new products discussed in this article include a surgical training model, devices designed to improve prostate biopsy accuracy, an updated label and more.
Why Remicade biosimilar sales will grow in the U.S.Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.
Roth spots show as initial presentation in multiple myelomaRoth spots are hemorrhages in the retina with white centers. They occur in a wide variety of systemic conditions that are associated with retinal hemorrhages.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Remicade will now have a biosimilarExpert: Expectations are high that biosimilars can control overall biologic cost growth.
Merger to boost eczema offeringsPfizer and Anacor Pharmaceuticals announced in May that the pharmaceutical companies merged with Pfizer acquiring Anacor for about $5.2 billion. Dermatologists say merger is a good move for patients.